Necrosis in a Biomarker-driven, Phase 2 Trial of Adjuvant Apatinib in Patients of Nasopharyngeal Carcinoma with Residual Epstein–Barr Virus DNA after Radiotherapy

Xu Liu,Ling Guo,Fang-Yun Xie,Wei-Han Hu,Ming-Yuan Chen,Qing-Mei He,Zhi-Min Xu,Chu-Qing Zhang,Ying-Lin Peng,Ling-Long Tang,Yan-Ping Mao,Rui Sun,Ji-Bin Li,Athanassios Argiris,Ying Sun,Jun Ma,Edwin P. Hui

DOI: https://doi.org/10.1016/j.ijrobp.2022.04.049

2022-05-10

Abstract:Background We previously demonstrated that real-time monitoring of plasma Epstein–Barr virus DNA (EBV DNA) during chemoradiotherapy defined four distinct phenotypic clusters of nasopharyngeal carcinoma. In particular, the treatment-resistant group, defined as detectable EBV DNA at the end of radiotherapy, had the worst prognosis and is thought to have minimal residual disease. Patients and Methods This is the first phase-2 trial to use a targeted agent, apatinib (an inhibitor of vascular endothelial growth factor [VEGF] receptor 2 tyrosine kinase), in the treatment-resistant group. Eligible patients had plasma EBV DNA >0 copies/mL at the end of radiotherapy (+/- 1 week). Patients received apatinib (500 mg, once-daily) until disease progression, unacceptable toxicity, or for a maximum of 2 years. The primary endpoint was disease-free survival (DFS). Results Twenty-five patients were enrolled and 23 patients who received apatinib were included in the analyses. Three-year DFS was 47.8% and overall survival (OS) was 73.9%. Patients with plasma VEGF-A ≤150 pg/ml at 28 days after the initiation of treatment had significantly better 3-year DFS (66.7% vs. 14.3%, P = 0.041) and OS (88.9% vs. 42.9%, P = 0.033). The most common adverse event of grade ≥3 was nasopharyngeal necrosis (26%), oral/pharyngeal pain (22%), and hand-foot syndrome (22%). Nineteen patients had serial EBV DNA data. Fourteen patients had plasma EBV DNA clearance (turn to 0) and 5 (36%) of these 14 patients had disease recurrence or death, whereas all five patients without EBV DNA clearance had disease recurrence or death (3-year DFS: 64.3% vs . 0%, P = 0.001). Conclusions The use of antiangiogenic agents shortly after radiotherapy might increase the risk of necrosis. This approach needs to be avoided until translational and preclinical studies revealed the underlying mechanism of interaction between radiotherapy and antiangiogenic agents. Trial registration ClinicalTrials.gov, NCT********.

oncology,radiology, nuclear medicine & medical imaging